SCHEMBL107333

SCHEMBL107333

COP(=O)(CC(C)=O)OC

nearest known ligand 0.39

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.38
GAA P10253 1/20 0.38
SI P14410 1/20 0.38
MGAM2 Q2M2H8 1/20 0.38
ALDH1A1 P00352 3/20 0.33
TDP1 Q9NUW8 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
TRPA1 O75762 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27690196 0.82 LMNA (0.31) ALDH1A1LMNAPOLB
SCHEMBL11042103 0.80 POLB (0.34) LMNAPOLB
SCHEMBL29169988 0.79 MGAM (0.35) MGAMGAASIMGAM2ALDH1A1
SCHEMBL51192 0.78 LMNA (0.46) GAAALDH1A1TDP1LMNAPOLB
SCHEMBL19400765 0.76
SCHEMBL8563170 0.76 ALDH1A1 (0.36) MGAMGAASIMGAM2ALDH1A1
SCHEMBL19102478 0.76 ALDH1A1 (0.32) MGAMGAASIMGAM2ALDH1A1
SCHEMBL13914924 0.76 LMNA (0.32) LMNAPOLB
SCHEMBL2978610 0.76
SCHEMBL27742533 0.76 LMNA (0.32) ALDH1A1TDP1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 804 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400793-A1 COMPOSITION FOR POLYURETHANE FOAM, FOAM PREPARED THEREFROM AND A METHOD THEREOF MOMENTIVE PERFORMANCE MATERIALS INC. 2024-12-05 US claimed
EP-4396271-A1 COMPOSITION FOR POLYURETHANE FOAM, FOAM PREPARED THEREFROM AND A METHOD THEREOF Momentive Performance Materials Inc. (US) 2024-07-10 EP claimed
CN-117843599-A Preparation method of prostaglandin intermediate containing 1-alkyl-1-alkenyl ethanol structure 广州楷石医药有限公司 2024-04-09 CN claimed
WO-2023034354-A1 COMPOSITION FOR POLYURETHANE FOAM, FOAM PREPARED THEREFROM AND A METHOD THEREOF MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2023-03-09 WO claimed
CN-115611760-A Chemical synthesis method suitable for large-scale production of (S) -2-amino-5-alkynyl caproic acid 天津药明康德新药开发有限公司 2023-01-17 CN claimed
CN-108569969-A A kind of synthetic method of 3-aminophenylacetylene 西安格瑞德化工新材料有限公司 2018-09-25 CN claimed
CN-106188006-A Containing 1,2,3 triazole heterocycle compounds and its preparation method and application 天津国际生物医药联合研究院 2016-12-07 CN claimed
CN-103724211-A Preparation method for m-aminophenylacetylene CHONGQING WORLD HAORUI PHARM CHEM CO LTD 2014-04-16 CN claimed
US-8471043-B2 Platensimycin derivatives, their intermediates, and process for preparing the same, and new process for preparing platensimycin SNU R&DB FOUNDATION (KR) 2013-06-25 US claimed
US-20120264011-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2012-10-18 US claimed
US-20110028741-A1 Novel Platensimycin Derivatives, Their Intermediates, and Process for Preparing the Same, and New Process for Preparing Platensimycin SNU R&DB FOUNDATION (KR) 2011-02-03 US claimed
WO-2009125938-A2 NOVEL PLATENSIMYCIN DERIVATIVES, THEIR INTERMEDIATES, AND PROCESS FOR PREPARARING THE SAME, AND NEW PROCESS FOR PREPARING PLATENSIMYCIN SNU R&DB FOUNDATION (KR) 2009-10-15 WO claimed
US-6552239-B1 Reacting ketophosphonate with diazo-transfer reagent generating a ketodiazophosphonate which is reacted with cyclopropanecarboxaldehyde MERCK & CO., INC. 2003-04-22 US claimed
EP-0912467-B1 ASYMMETRIC HYDROGENATION METHOD OF A KETONIC COMPOUND AND DERIVATIVE RHODIA CHIMIE SA (FR) 2002-04-24 EP claimed
US-4338466-A PRECURSORS FOR OLIGOMERS EXHIBITING PROTECTION FOR OXIDATIVE PHOSPHORYLATION OF DEGENERATED MITOCHONDRIA THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 1982-07-06 US claimed
CN-122094688-A Compositions and methods for treating pulmonary arterial hypertension 2026-05-26 CN disclosed
US-12570617-B2 Use of triazole compound as ghrelin receptor agonist KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2026-03-10 US disclosed
EP-0121117-A1 Derivatives of dihydropyridine and production thereof NIPPON SHINYAKU COMPANY, LIMITED (JP) 1984-10-10 EP disclosed
US-4388237-A NEUROLEPTIC, SEDATIVE, HYPNOTIC, ANALGESIC, ANTIDEPRESSANT BASF AKTIENGESELLSCHAFT (DE) 1983-06-14 US disclosed
US-4246103-A INHIBIT PRECIPITATION OF HARD WATER IONS ESPECIALLY FOR INDUSTRIAL WATER AND SLUDGE BAYER AKTIENGESELLSCHAFT (DE) 1981-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028741-A1 Novel Platensimycin Derivatives, Their Intermediates, and Process for Preparing the Same, and New Process for Preparing Platensimycin RPN2, RPN1, DHPS MGAM 410/4885GAA 1097/4885SI 390/4885
US-12570617-B2 Use of triazole compound as ghrelin receptor agonist GIPR, GLP1R, GCGR MGAM 3851/4885GAA 3251/4885SI 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.